Combined modality therapy with TRAIL or agonistic death receptor antibodies. - Test2 - elhamkhani - TriplyDB

Combined modality therapy with TRAIL or agonistic death receptor antibodies.

Combined modality therapy with TRAIL or agonistic death receptor antibodies.

http://www.wikidata.org/entity/Q37832083

about

Computational modelling of LY303511 and TRAIL-induced apoptosis suggests dynamic regulation of cFLIP Superior antitumoral activity of dimerized targeted single-chain TRAIL fusion proteins under retention of tumor selectivity WEE1 inhibition sensitizes basal breast cancer cells to TRAIL-induced apoptosis.Molecular targeted approaches for treatment of pancreatic cancer.Tumor priming by Apo2L/TRAIL reduces interstitial fluid pressure and enhances efficacy of liposomal gemcitabine in a patient derived xenograft tumor model.Mislocalization of death receptors correlates with cellular resistance to their cognate ligands in human breast cancer cells Low-dose anisomycin sensitizes melanoma cells to TRAIL induced apoptosis hnRNPK inhibits GSK3β Ser9 phosphorylation, thereby stabilizing c-FLIP and contributes to TRAIL resistance in H1299 lung adenocarcinoma cells.Effect of anti-DR5 and chemotherapy on basal-like breast cancer.Depletion of CABYR-a/b sensitizes lung cancer cells to TRAIL-induced apoptosis through YAP/p73-mediated DR5 upregulation.Molecular Signaling in Benign Odontogenic Neoplasia Pathogenesis TRAIL on trial: preclinical advances in cancer therapy Engineered adenovirus fiber shaft fusion homotrimer of soluble TRAIL with enhanced stability and antitumor activity.Functional TRAIL receptors in monocytes and tumor-associated macrophages: A possible targeting pathway in the tumor microenvironment Sensitization of (colon) cancer cells to death receptor related therapies: a report from the FP6-ONCODEATH research consortium.Using natural products to promote caspase-8-dependent cancer cell death.Combining trail with PI3 kinase or HSP90 inhibitors enhances apoptosis in colorectal cancer cells via suppression of survival signaling.Snake venom toxin from Vipera lebetina turanica sensitizes cancer cells to TRAIL through ROS- and JNK-mediated upregulation of death receptors and downregulation of survival proteins.AW00179 potentiates TRAIL-mediated death of human lung cancer H1299 cells through ROS-JNK-c-Jun-mediated up-regulation of DR5 and down-regulation of anti-apoptotic molecules.Cell cycle-arrested tumor cells exhibit increased sensitivity towards TRAIL-induced apoptosis.TRAIL DR5-CTSB crosstalk participates in breast cancer autophagy initiated by SAHA.The plant alkaloid and anti-leukemia drug homoharringtonine sensitizes resistant human colorectal carcinoma cells to TRAIL-induced apoptosis via multiple mechanisms.

P2860

Q28393929-8B2F7B0E-09A0-41AD-BED0-7B499A65F220 Q28729760-3D77C101-F55F-4EBE-AEDE-5E94CE81EB99 Q35683131-12B895C2-0236-4591-A90F-67E04137CC16 Q36174910-64DCD9FA-952C-48C5-A14C-1315CC17B91B Q36218165-BFFAFBFB-AB03-40E2-99C2-39E5B28BAB2A Q36339240-FEE6C4BB-A127-45AD-8C7C-A527ECA32E90 Q36608713-3F96C181-767E-42F2-9ED9-B02781926773 Q36681641-1B45FC50-6F4E-4207-89A4-14CB46BD17EE Q36731275-9B19CC43-E77C-493F-BAFC-5E1A6906817A Q36962657-FD3BCF80-1277-421A-9951-5B1CEF5E65B1 Q37183900-57811C0E-FD40-4C04-B992-66BC86070F48 Q37433463-45EF71AD-E65C-4359-9A77-E72A7EAA4AC1 Q37482834-F9BADE15-7B32-41B2-A378-68318B5BC0A5 Q37520325-0B8270E2-E495-4868-811F-C96FB0EC0790 Q37992502-E88AEC27-5410-4CE3-8CC8-18157ACF04FD Q38861356-B64D5826-4401-4EC2-9958-C49ABACDEF09 Q39126075-AFEB1BA6-D27E-4184-8773-36290438BAE4 Q39272664-31E7742B-FA69-4BB2-95C3-DBE24A8A55E7 Q39392672-5BFCA373-6CF0-46C9-907C-9719C2DC8BB6 Q39406143-E0279B6F-DE98-4AD6-9918-DF059A855F97 Q41987802-75EC5F22-3024-4E25-850A-E45BE49C53DF Q43468001-19991236-57EA-47C1-9749-DC86E9BDFC59

P2860

Combined modality therapy with TRAIL or agonistic death receptor antibodies.

http://www.wikidata.org/entity/Q37832083

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on March 2011

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Combined modality therapy with TRAIL or agonistic death receptor antibodies.

@en

Combined modality therapy with TRAIL or agonistic death receptor antibodies.

@nl

type

label

Combined modality therapy with TRAIL or agonistic death receptor antibodies.

@en

Combined modality therapy with TRAIL or agonistic death receptor antibodies.

@nl

prefLabel

Combined modality therapy with TRAIL or agonistic death receptor antibodies.

@en

Combined modality therapy with TRAIL or agonistic death receptor antibodies.

@nl

P1433

Q37832083-C8731D4D-114F-4569-AB33-27E1065C00E9

P1476

Q37832083-A4179520-DA87-4AD4-80E7-A0E6C1A4005D

P2093

Q37832083-5FD0B2C1-B409-4FFF-B2B3-527DC338D743

Q37832083-7AFCC7CF-6770-4FFC-A029-BE3AB4E5D927

Q37832083-970AB229-11F6-45D8-BAD5-51CD12B960F4

Q37832083-C733E60E-42F2-4600-81F0-8102286EFC16

P2860

Q37832083-00D2F44A-228E-49A3-B912-15CC45D7C3E8

Q37832083-01278E74-BF1F-4E94-8798-2876FA5EF829

Q37832083-041ED0C9-2E0D-4198-9C75-F9EAAEFB8DD4

Q37832083-06E690D6-4A10-4859-AD07-BDB2C0E76EAD

Q37832083-079C28B7-351E-4739-9D1C-159AD3E7744C

Q37832083-0CA2943B-179C-45C0-B4B8-D0C93045D3A3

Q37832083-0D1C26BB-0C12-49FD-B0D7-58AA42E30F11

Q37832083-0D5D15E6-CA43-4DF2-AF9C-1677C2283C86

Q37832083-0D6594BA-A72D-4B75-9324-6F6BB523B7EA

Q37832083-0DD1BC76-297C-45E2-AA96-41EEAD6DBAF6

P304

Q37832083-202FF7BD-16A7-4F58-9616-2543F3BA5C31

P31

Q37832083-3A58E0AB-0438-4E3D-99C4-96DD41BDD1BF

P356

Q37832083-5E1C8AC5-753F-4C8D-B2C5-6F2A2A188248

P433

Q37832083-A88F5733-B130-47A4-AEBB-233047EC2292

P478

Q37832083-FDF4C9DB-3F24-4BF3-A142-E0D89B4AFAC4

P50

Q37832083-F2F6682F-D10B-426C-9956-4DE63024DD5B

P577

Q37832083-C3C6F135-866A-4865-B197-AA2B8A70FDDD

P5875

Q37832083-E8FEFB6A-F232-4557-84E6-EDCF4A86460D

P698

Q37832083-57EC5F26-7688-4E55-AE8E-750CE807AB8A

P921

Q37832083-3E23F2D4-1EAF-4B96-8FFD-85801E9D054A

P932

Q37832083-47CAF850-C540-4D29-9D48-A18B958AEC85

P356

P1433

Cancer Biology and Therapy

P1476

Combined modality therapy with TRAIL or agonistic death receptor antibodies

@en

P2093

Choo Hyung Lee

http://www.w3.org/2001/XMLSchema#string

Hope M Amm

http://www.w3.org/2001/XMLSchema#string

Patsy G Oliver

http://www.w3.org/2001/XMLSchema#string

Yufeng Li

http://www.w3.org/2001/XMLSchema#string

P2860

Characterization of two receptors for TRAIL

The receptor for the cytotoxic ligand TRAIL

TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL.

Identification and characterization of a new member of the TNF family that induces apoptosis

The novel receptor TRAIL-R4 induces NF-kappaB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain

Death receptor 5, a new member of the TNFR family, and DR4 induce FADD-dependent apoptosis and activate the NF-kappaB pathway

Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family

Interaction of Beclin 1 with survivin regulates sensitivity of human glioma cells to TRAIL-induced apoptosis

Increased expression of death receptors 4 and 5 synergizes the apoptosis response to combined treatment with etoposide and TRAIL

HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo

P304

431-449

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4161/CBT.11.5.14671

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P50

Donald J Buchsbaum

P577

2011-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49781922

http://www.w3.org/2001/XMLSchema#string

P698

21263219

http://www.w3.org/2001/XMLSchema#string

P921

P932

3087899

http://www.w3.org/2001/XMLSchema#string